Cipla gets nod for generic version of Shire’s Firazyr

Pharma major Cipla has announced that the company has received the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.The purpose of the Icatibant injection is for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

  • Related Posts

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    India’s pharmaceutical exports rose more than 2% year on year to $31.11 billion in FY26 despite a 23% decline in March amid the fallout of the West Asia war. A…

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS